Ewing sarcoma is a type of cancer that primarily affects the bone. It is triggered when normal cells in the bone change into abnormal cells and grow uncontrollably. However, in some cases, Ewing sarcoma starts in tissues outside of the bone.
Although this cancer is highly prevalent among children and teens between the ages 10 and 20, adults might also be susceptible to it. Ewing sarcoma most often affects bones in the legs, arms, and pelvis I causing pain, tenderness, and swelling. The pain may arrive and subside, but can get gets worse over weeks to months. This pain is usually worse at night and causes discomfort when exercising. According to WHO report, primary bone tumor is responsible for nearly 5% of all cancers in youth and Ewing sarcoma is the second most common bone tumor in this age group. Incidence of Ewing sarcoma was estimated to be approximately 3 per 1,000,000 in the U.S. between 1973 and 2004.
COVID-19 Impact Analysis
Patients with cancer particularly are at significant risk of morbidity and mortality due to their immunocompromised state. If sarcomas are treated on time, they have good oncological outcomes, which are safer than many other cancers. The risk of acquiring COVID-19 has to be balanced against the need to treat the malignancy.
Surgical management forms the foundation for treating bone and soft tissue sarcomas and is considered a semi-emergency; the timing of surgery has significant implications on the outcome of these patients. This underlying fact remains unchanged in COVID-19 particularly for high-grade bone and soft tissue sarcomas. During the COVID-19 pandemic, with the forthcoming uncertainty of how the pandemic unfolds during the coming months, three major apprehensions surround decisions regarding surgery for bone and soft tissue sarcomas:
- Higher risk of postoperative morbidity and mortality in patients suffering from COVID-19, more so in cancer patients.
- Protection of healthcare workers from COVID-19 infection from patients undergoing surgery.
- Utilization of valuable resources (e.g., ICU beds/blood &blood products/PPEs/ventilators/oxygen), which may be required, should there be a steep rise in other COVID-19 patients requiring hospitalization.
Top Impacting Factors
- Escalating incidences of Ewing sarcoma globally is driving the market growth.
- Initiatives taken by government organizations to decrease the rate of morbidity caused by Ewing sarcoma also enhances the growth of this market.
- A surge in R&D activities to introduce an approved and effective treatment for Ewing sarcoma by leading companies can act as a market driver.
- For treating Ewing sarcoma, no approved treatment is available which may restrict the growth of this market.
- Moreover, the high cost of chemotherapy and lack of awareness among people about Ewing sarcoma may hamper the growth of this market.
- The focus on advancing regenerative medicines in clinical phases is supposed to have a positive impact on the overall market growth.
Market Trends
New Product Launches to Flourish the Market
- In January 2018, a new drug target known as CDK12 inhibitor was discovered for the treatment of Ewing sarcoma at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. The CDK12 inhibition destroys the Ewing sarcoma cells by bringing in a surge of hope to the field of pediatric oncology.
Key Benefits of the Report
- This study presents the analytical depiction of the Ewing sarcoma drug market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Ewingsarcoma drug market share.
- The current market is quantitatively analyzed to highlight the Ewing sarcoma drug market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
- The report provides a detailed Ewing sarcoma drug market analysis based on the competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Ewing Sarcoma Drug Market Report
- Who are the leading players active in the Ewing sarcoma drug market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What future projections would help in taking further strategic steps?
- What is "Ewing sarcoma"?
- What is "the Ewing sarcoma drug" market prediction in the future?
- Who are the leading global players in the "the Ewing sarcoma drug" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "the Ewing sarcoma drug" market report?
Key Market Segments
- By Product Type
- Bone Tumor
- Peripheral Primitive Neuroectodermal Tumor
- Askin Tumor
- Soft Tissue Tumor
- By Application
- Chemotherapy
- Surgery
- Radiation
- By End User
- Hospital
- Specialty Clinic
- Homecare
- Others
- By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- AstraZeneca
- GlaxoSmithKline plc,
- Abbott Laboratories
- Novartis AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Bayer AG
- Johnson and Johnson, Inc.
- F. Hoffmann-La Roche Ltd.